Literature DB >> 30734573

Serotonin levels and 1-year mortality in patients with neuroendocrine tumors: a systematic review and meta-analysis.

Vijay N Joish1, Sandip Shah2, Jonothan C Tierce2, Deep Patel2, Chad McKee1, Pablo Lapuerta1, Jerome Zacks3.   

Abstract

Aim: Elevated serotonin in patients with neuroendocrine tumors (NETs) may impact heart failure incidence but a quantitative relationship has not been established. Materials & methods: Systematic review and meta-analysis of studies assessing 24-h urinary 5-hydroxyindoleacetic acid (u5-HIAA) and mortality in patients with NETs (2007-2017) with a primary outcome of 1-year mortality risk and 24-h u5-HIAA.
Results: We identified 1715 records of which 12 studies including 755 patients (3442 person-years with 376 deaths) were eligible for meta-analysis. Mean u5-HIAA was 149.2 mg/24 h (standard deviation: 96.6) and mortality was 13.0%. The meta-regression equation showed an 11.8% (95% CI: 8.9-17.0%; I2  = 93.0%) increase in 1-year mortality for every ten-unit increase in u5-HIAA.
Conclusion: Serotonin measured by its metabolite u5-HIAA is predictive of 1-year all-cause mortality in patients with NETs.

Entities:  

Keywords:  carcinoid syndrome; mortality; neuroendocrine tumors; serotonin

Mesh:

Substances:

Year:  2019        PMID: 30734573     DOI: 10.2217/fon-2018-0960

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  5 in total

1.  Antiproliferative Effects of Telotristat Ethyl in Patients with Neuroendocrine Tumors: The TELEACE Real-World Chart Review Study.

Authors:  Michael A Morse; Eric Liu; Vijay N Joish; Lynn Huynh; Mu Cheng; Mei Sheng Duh; Kiernan Seth; Pablo Lapuerta; David C Metz
Journal:  Cancer Manag Res       Date:  2020-07-30       Impact factor: 3.989

2.  Survival and Clinical Outcomes with Telotristat Ethyl in Patients with Carcinoid Syndrome.

Authors:  David C Metz; Eric Liu; Vijay N Joish; Lynn Huynh; Todor I Totev; Mei Sheng Duh; Kiernan Seth; Susan Giacalone; Pablo Lapuerta; Michael A Morse
Journal:  Cancer Manag Res       Date:  2020-10-07       Impact factor: 3.989

Review 3.  Recent advances in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms.

Authors:  Meng Dai; Christina S Mullins; Lili Lu; Guido Alsfasser; Michael Linnebacher
Journal:  World J Gastrointest Surg       Date:  2022-05-27

4.  Changes in Carcinoid Syndrome Symptoms Among Patients Receiving Telotristat Ethyl in US Clinical Practice: Findings from the TELEPRO-II Real-World Study.

Authors:  Matthew H Kulke; Hagen F Kennecke; Kris Murali; Vijay N Joish
Journal:  Cancer Manag Res       Date:  2021-09-27       Impact factor: 3.989

Review 5.  Carcinoid Heart Disease: How to Diagnose and Treat in 2020?

Authors:  Barbara Bober; Marek Saracyn; Maciej Kołodziej; Łukasz Kowalski; Elżbieta Deptuła-Krawczyk; Waldemar Kapusta; Grzegorz Kamiński; Olga Mozenska; Jacek Bil
Journal:  Clin Med Insights Cardiol       Date:  2020-10-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.